News | August 02, 2023
Bliss GVS Pharma Q1 FY2024 consolidated PAT up at Rs. 14.68 Cr
The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023
The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
More than 9600 Pradhan Mantri Bhartiya Janaushadhi Kendras have been set up covering all districts of the country to promote generic medicines at affordable prices
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
The company has reported total income of Rs. 6738.4 crores during the period ended June 30, 2023
Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023
Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1052.79 crores during the period ended June 30, 2023
Subscribe To Our Newsletter & Stay Updated
